The immune microenvironment of the colorectal tumor: Involvement of immunity genes and microRNAs belonging to the TH17 pathway

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1856, Issue 1, 2015, Pages 28-38

  Omrane, Inés ^a   Benammar Elgaaied, Amel ^a  

^a FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

Author keywords

Colorectal cancer; Immunity; Inflammation; MicroRNA; TH17 pathway

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 6; MICRORNA; MICRORNA 135A; MICRORNA 146A; MICRORNA 147B; MICRORNA 155; MICRORNA 21; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE;

ADAPTIVE IMMUNITY; CANCER GROWTH; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CARD15 GENE; COLON CANCER; COLORECTAL CANCER; EPIGENETICS; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; IMMUNOGENETICS; INFLAMMATION; INNATE IMMUNITY; LYMPH NODE METASTASIS; NOD2 GENE; PRIORITY JOURNAL; PROTEIN RNA BINDING; RECTUM CANCER; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL; TLR4 GENE; TUMOR DIFFERENTIATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; COLORECTAL TUMOR; GENETICS; IMMUNOLOGY;

ADAPTIVE IMMUNITY; COLORECTAL NEOPLASMS; CYTOKINES; HUMANS; IMMUNITY, INNATE; MICRORNAS; TH17 CELLS; TUMOR MICROENVIRONMENT;

EID: 84929630054     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2015.04.001     Document Type: Review

References (101)

1. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., Bos J.L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988, 319:525-532.
2. Mantovani A. Cancer: inflammation by remote control. Nature 2005, 435:752-753.
3. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117:1175-1183.
4. Sun J., Wiklund F., Hsu F.C., Balter K., Zheng S.L., Johansson J.E., Chang B., Liu W., Li T., Turner A.R., Li L., Li G., Adami H.O., Isaacs W.B., Xu J., Gronberg H. Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 2006, 15:480-485.
5. A. Gast, J.L. Bermejo, R. Claus, A. Brandt, M. Weires, A. Weber, C. Plass, A. Sucker, K. Hemminki, D. Schadendorf, R. Kumar, Association of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survival, PloS One, 6 e24370.
6. Hold G.L., Rabkin C.S., Chow W.H., Smith M.G., Gammon M.D., Risch H.A., Vaughan T.L., McColl K.E., Lissowska J., Zatonski W., Schoenberg J.B., Blot W.J., Mowat N.A., Fraumeni J.F., El-Omar E.M. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007, 132:905-912.
7. P. Pimentel-Nunes, A.L. Teixeira, C. Pereira, M. Gomes, C. Brandao, C. Rodrigues, N. Goncalves, I. Boal-Carvalho, R. Roncon-Albuquerque, Jr., L. Moreira-Dias, A.F. Leite-Moreira, R. Medeiros, M. Dinis-Ribeiro, Functional polymorphisms of Toll-like receptors 2 and 4 alter the risk for colorectal carcinoma in Europeans, Dig Liver Dis, 45 63-69.
8. Y. Shen, Y. Liu, S. Liu, A. Zhang, Toll-like Receptor 4 Gene polymorphisms and susceptibility to bladder cancer, Pathol Oncol Res.
9. G.E. Theodoropoulos, V. Saridakis, T. Karantanos, N.V. Michalopoulos, F. Zagouri, P. Kontogianni, M. Lymperi, M. Gazouli, G.C. Zografos, Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development, Breast (Edinburgh, Scotland), 21 534-538.
10. Zheng S.L., Augustsson-Balter K., Chang B., Hedelin M., Li L., Adami H.O., Bensen J., Li G., Johnasson J.E., Turner A.R., Adams T.S., Meyers D.A., Isaacs W.B., Xu J., Gronberg H. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res. 2004, 64:2918-2922.
11. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., Achkar J.P., Brant S.R., Bayless T.M., Kirschner B.S., Hanauer S.B., Nunez G., Cho J.H. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
12. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., Almer S., Tysk C., O'Morain C.A., Gassull M., Binder V., Finkel Y., Cortot A., Modigliani R., Laurent-Puig P., Gower-Rousseau C., Macry J., Colombel J.F., Sahbatou M., Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
13. Lesage S., Zouali H., Cezard J.P., Colombel J.F., Belaiche J., Almer S., Tysk C., O'Morain C., Gassull M., Binder V., Finkel Y., Modigliani R., Gower-Rousseau C., Macry J., Merlin F., Chamaillard M., Jannot A.S., Thomas G., Hugot J.P. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am. J. Hum. Genet. 2002, 70:845-857.
14. Papaconstantinou I., Theodoropoulos G., Gazouli M., Panoussopoulos D., Mantzaris G.J., Felekouras E., Bramis J. Association between mutations in the CARD15/NOD2 gene and colorectal cancer in a Greek population. Int. J. Cancer 2005, 114:433-435.
15. Y. Tian, Y. Li, Z. Hu, D. Wang, X. Sun, C. Ren, Differential effects of NOD2 polymorphisms on colorectal cancer risk: a meta-analysis, International Journal of Colorectal Disease, 25 161-168.
16. Omrane I., Baroudi O., Kourda N., Bignon Y.J., Uhrhammer N., Desrichard A., Medimegh I., Ayari H., Stambouli N., Mezlini A., Bouzayenne H., Marrakchi R., Benammar-Elgaaid A., Bougatef K. Positive link between variant Toll-like receptor 4 (Asp299Gly and Thr399Ile) and colorectal cancer patients with advanced stage and lymph node metastasis. Tumour Biol. 2014, 35:545-551.
17. Omrane I., Mezlini A., Baroudi O., Stambouli N., Bougatef K., Ayari H., Medimegh I., Bouzaienne H., Uhrhammer N., Bignon Y.J., Benammar-Elgaaied A., Marrakchi R. 3020insC NOD2/CARD15 polymorphism associated with treatment of colorectal cancer. Med. Oncol. (Northwood, London, England) 2014, 31:954.
18. M.L. Slattery, J.S. Herrick, K.L. Bondurant, R.K. Wolff, Toll-like receptor genes and their association with colon and rectal cancer development and prognosis, International Journal of Cancer, 130 2974-2980.
19. H. Davoodi, H.F. Seow, Variant Toll-like receptor4 (Asp299Gly and Thr399Ile alleles) and Toll-like receptor2 (Arg753Gln and Arg677Trp alleles) in colorectal cancer, Iranian Journal of Allergy, Asthma, and Immunology, 10 91-99.
20. Guo Q., Zhu J., Xia B. Polymorphism of CD14 gene but not the mutation of TLR4 gene is associated with colorectal cancer in Chinese patients. J. Gastroenterol. Hepatol. 2006, 21:92-97.
21. Lakatos P.L., Hitre E., Szalay F., Zinober K., Fuszek P., Lakatos L., Fischer S., Osztovits J., Gemela O., Veres G., Papp J., Ferenci P. Common NOD2/CARD15 variants are not associated with susceptibility or the clinicopathologic characteristics of sporadic colorectal cancer in Hungarian patients. BMC Cancer 2007, 7:54.
22. Alhopuro P., Ahvenainen T., Mecklin J.P., Juhola M., Jarvinen H.J., Karhu A., Aaltonen L.A. NOD2 3020insC alone is not sufficient for colorectal cancer predisposition. Cancer Res. 2004, 64:7245-7247.
23. Mockelmann N., von Schonfels W., Buch S., von Kampen O., Sipos B., Egberts J.H., Rosenstiel P., Franke A., Brosch M., Hinz S., Roder C., Kalthoff H., Folsch U.R., Krawczak M., Schreiber S., Broring C.D., Tepel J., Schafmayer C., Hampe J. Investigation of innate immunity genes CARD4, CARD8 and CARD15 as germline susceptibility factors for colorectal cancer. BMC Gastroenterol. 2009, 9:79.
24. Kurzawski G., Suchy J., Kladny J., Grabowska E., Mierzejewski M., Jakubowska A., Debniak T., Cybulski C., Kowalska E., Szych Z., Domagala W., Scott R.J., Lubinski J. The NOD2 3020insC mutation and the risk of colorectal cancer. Cancer Res. 2004, 64:1604-1606.
25. Suchy J., Klujszo-Grabowska E., Kladny J., Cybulski C., Wokolorczyk D., Szymanska-Pasternak J., Kurzawski G., Scott R.J., Lubinski J. Inflammatory response gene polymorphisms and their relationship with colorectal cancer risk. BMC Cancer 2008, 8:112.
26. Roberts R.L., Gearry R.B., Allington M.D., Morrin H.R., Robinson B.A., Frizelle F.A. Caspase recruitment domain-containing protein 15 mutations in patients with colorectal cancer. Cancer Res. 2006, 66:2532-2535.
27. A. Eyking, B. Ey, M. Runzi, A.I. Roig, H. Reis, K.W. Schmid, G. Gerken, D.K. Podolsky, E. Cario, Toll-like receptor 4 variant D299G induces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer, Gastroenterology, 141 2154-2165.
28. E.L. Wang, Z.R. Qian, M. Nakasono, T. Tanahashi, K. Yoshimoto, Y. Bando, E. Kudo, M. Shimada, T. Sano, High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer, British Journal of Cancer, 102 908-915.
29. Simiantonaki N., Kurzik-Dumke U., Karyofylli G., Jayasinghe C., Michel-Schmidt R., Kirkpatrick C.J. Reduced expression of TLR4 is associated with the metastatic status of human colorectal cancer. Int. J. Mol. Med. 2007, 20:21-29.
30. Jia H.P., Kline J.N., Penisten A., Apicella M.A., Gioannini T.L., Weiss J., McCray P.B. Endotoxin responsiveness of human airway epithelia is limited by low expression of MD-2. Am. J. Physiol. 2004, 287:L428-L437.
31. P. Prohinar, P. Rallabhandi, J.P. Weiss, T.L. Gioannini, Expression of functional D299G.T399I polymorphic variant of TLR4 depends more on coexpression of MD-2 than does wild-type TLR4, J Immunol, 184 4362-4367.
32. Tosolini M., Kirilovsky A., Mlecnik B., Fredriksen T., Mauger S., Bindea G., Berger A., Bruneval P., Fridman W.H., Pages F., Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011, 71:1263-1271.
33. Kryczek I., Wei S., Zou L., Altuwaijri S., Szeliga W., Kolls J., Chang A., Zou W. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 2007, 178:6730-6733.
34. Wang J., Wang X., Gong W., Mi B., Liu S., Jiang B. Increased expression of beta-catenin, phosphorylated glycogen synthase kinase 3beta, cyclin D1, and c-myc in laterally spreading colorectal tumors. J. Histochem. Cytochem. 2009, 57:363-371.
35. Omrane I., Marrakchi R., Baroudi O., Mezlini A., Ayari H., Medimegh I., Stambouli N., Kourda N., Bouzaienne H., Uhrhammer N., Bougatef K., Bignon Y.J., Benammar-Elgaaied A. Significant association between interleukin-17A polymorphism and colorectal cancer. Tumour Biol. 2014, 35:6627-6632.
36. Omrane I., Baroudi O., Bougatef K., Mezlini A., Abidi A., Medimegh I., Stambouli N., Ayari H., Kourda N., Uhrhammer N., Bignon Y.J., Benammar Elgaaied A., Marrakchi R. Significant association between IL23R and IL17F polymorphisms and clinical features of colorectal cancer. Immunol. Lett. 2014, 158:189-194.
37. Zhou B., Zhang P., Wang Y., Shi S., Zhang K., Liao H., Zhang L. Interleukin-17 gene polymorphisms are associated with bladder cancer in a Chinese Han population. Mol. Carcinog. 2012, 52:871-878.
38. Quan Y., Zhou B., Wang Y., Duan R., Wang K., Gao Q., Shi S., Song Y., Zhang L., Xi M. Association between IL17 polymorphisms and risk of cervical cancer in Chinese women. Clin. Dev. Immunol. 2012, 2012:258293.
39. Wang L., Jiang Y., Zhang Y., Wang Y., Huang S., Wang Z., Tian B., Yang Y., Jiang W., Pang D. Association analysis of IL-17A and IL-17F polymorphisms in Chinese Han women with breast cancer. PLoS One 2012, 7:e34400.
40. Shibata T., Tahara T., Hirata I., Arisawa T. Genetic polymorphism of interleukin-17A and -17F genes in gastric carcinogenesis. Hum. Immunol. 2009, 70:547-551.
41. Wu X., Zeng Z., Chen B., Yu J., Xue L., Hao Y., Chen M., Sung J.J., Hu P. Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer. Int. J. Cancer 2010, 127:86-92.
42. Xiong B., Cheng Y., Ma L., Zhang C. MiR-21 regulates biological behavior through the PTEN/PI-3K/Akt signaling pathway in human colorectal cancer cells. Int. J. Oncol. 2013, 42:219-228.
43. J. Zheng, L. Jiang, L. Zhang, L. Yang, J. Deng, Y. You, N. Li, H. Wu, W. Li, J. Lu, Y. Zhou, Functional genetic variations in the IL-23 receptor gene are associated with risk of breast, lung and nasopharyngeal cancer in Chinese populations, Carcinogenesis, 33 2409-2416.
44. Z. Tong, X.O. Yang, H. Yan, W. Liu, X. Niu, Y. Shi, W. Fang, B. Xiong, Y. Wan, C. Dong, A protective role by interleukin-17F in colon tumorigenesis, PloS One, 7 e34959.
45. G. Radosavljevic, B. Ljujic, I. Jovanovic, Z. Srzentic, S. Pavlovic, N. Zdravkovic, M. Milovanovic, D. Bankovic, M. Knezevic, L.J. Acimovic, N. Arsenijevic, Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma, Neoplasma, 57 135-144.
46. Andreyev H.J., Norman A.R., Cunningham D., Oates J., Dix B.R., Iacopetta B.J., Young J., Walsh T., Ward R., Hawkins N., Beranek M., Jandik P., Benamouzig R., Jullian E., Laurent-Puig P., Olschwang S., Muller O., Hoffmann I., Rabes H.M., Zietz C., Troungos C., Valavanis C., Yuen S.T., Ho J.W., Croke C.T., O'Donoghue D.P., Giaretti W., Rapallo A., Russo A., Bazan V., Tanaka M., Omura K., Azuma T., Ohkusa T., Fujimori T., Ono Y., Pauly M., Faber C., Glaesener R., de Goeij A.F., Arends J.W., Andersen S.N., Lovig T., Breivik J., Gaudernack G., Clausen O.P., De Angelis P.D., Meling G.I., Rognum T.O., Smith R., Goh H.S., Font A., Rosell R., Sun X.F., Zhang H., Benhattar J., Losi L., Lee J.Q., Wang S.T., Clarke P.A., Bell S., Quirke P., Bubb V.J., Piris J., Cruickshank N.R., Morton D., Fox J.C., Al-Mulla F., Lees N., Hall C.N., Snary D., Wilkinson K., Dillon D., Costa J., Pricolo V.E., Finkelstein S.D., Thebo J.S., Senagore A.J., Halter S.A., Wadler S., Malik S., Krtolica K., Urosevic N. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br. J. Cancer 2001, 85:692-696.
47. Slaby O., Svoboda M., Michalek J., Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol. Cancer 2009, 8:102.
48. Sarver A.L., French A.J., Borralho P.M., Thayanithy V., Oberg A.L., Silverstein K.A., Morlan B.W., Riska S.M., Boardman L.A., Cunningham J.M., Subramanian S., Wang L., Smyrk T.C., Rodrigues C.M., Thibodeau S.N., Steer C.J. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 2009, 9:401.
49. Omrane I., Kourda N., Stambouli N., Privat M., Medimegh I., Arfaoui A., Uhrhammer N., Bougatef K., Baroudi O., Bouzaienne H., Marrakchi R., Bignon Y.J., Benammar-Elgaaied A. MicroRNAs 146a and 147b biomarkers for colorectal tumor's localization. BioMed research international 2014, 2014:584852.
50. Sheedy F.J., Palsson-McDermott E., Hennessy E.J., Martin C., O'Leary J.J., Ruan Q., Johnson D.S., Chen Y., O'Neill L.A. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat. Immunol. 2009, 11:141-147.
51. Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12481-12486.
52. Ghorpade D.S., Sinha A.Y., Holla S., Singh V., Balaji K.N. NOD2-nitric oxide-responsive microRNA-146a activates Sonic hedgehog signaling to orchestrate inflammatory responses in murine model of inflammatory bowel disease. J. Biol. Chem. 2013, 288:33037-33048.
53. Schulte L.N., Westermann A.J., Vogel J. Differential activation and functional specialization of miR-146 and miR-155 in innate immune sensing. Nucleic Acids Res. 2012, 41:542-553.
54. Okayama H., Schetter A.J., Harris C.C. MicroRNAs and inflammation in the pathogenesis and progression of colon cancer. Dig. Dis. (Basel, Switzerland) 2012, 30(Suppl. 2):9-15.
55. Si M.L., Zhu S., Wu H., Lu Z., Wu F., Mo Y.Y. miR-21-mediated tumor growth. Oncogene 2007, 26:2799-2803.
56. Yang L., Belaguli N., Berger D.H. MicroRNA and colorectal cancer. World J. Surg. 2009, 33:638-646.
57. Xu Y., Sun J., Xu J., Li Q., Guo Y., Zhang Q. miR-21 is a promising novel biomarker for lymph node metastasis in patients with gastric cancer. Gastroenterol. Res. Pract. 2012, 2012:640168.
58. Hezova R., Kovarikova A., Bienertova-Vasku J., Sachlova M., Redova M., Vasku A., Svoboda M., Radova L., Kiss I., Vyzula R., Slaby O. Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J. Gastroenterol. 2012, 18:2827-2831.
59. Ma L., Zhu L., Gu D., Chu H., Tong N., Chen J., Zhang Z., Wang M. A genetic variant in miR-146a modifies colorectal cancer susceptibility in a Chinese population. Arch. Toxicol. 2013, 87:825-833.
60. 1 expression and metastatic capability of human pancreatic cancer. Oncology 2003, 65:167-173.
61. Voronov E., Shouval D.S., Krelin Y., Cagnano E., Benharroch D., Iwakura Y., Dinarello C.A., Apte R.N. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2645-2650.
62. Zeng Y.L., Shao X.M., Li H.S. Numb expression in colon cancer and its significance. Sichuan da xue xue bao. Yi xue ban 2012, 43(14):6-8.
63. Niimoto T., Nakasa T., Ishikawa M., Okuhara A., Izumi B., Deie M., Suzuki O., Adachi N., Ochi M. MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet. Disord. 2010, 11:209.
64. Xia P., Fang X., Zhang Z.H., Huang Q., Yan K.X., Kang K.F., Han L., Zheng Z.Z. Dysregulation of miRNA146a versus IRAK1 induces IL-17 persistence in the psoriatic skin lesions. Immunol. Lett. 2012, 148:151-162.
65. Gironella M., Seux M., Xie M.J., Cano C., Tomasini R., Gommeaux J., Garcia S., Nowak J., Yeung M.L., Jeang K.T., Chaix A., Fazli L., Motoo Y., Wang Q., Rocchi P., Russo A., Gleave M., Dagorn J.C., Iovanna J.L., Carrier A., Pebusque M.J., Dusetti N.J. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:16170-16175.
66. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., Menard S., Palazzo J.P., Rosenberg A., Musiani P., Volinia S., Nenci I., Calin G.A., Querzoli P., Negrini M., Croce C.M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65:7065-7070.
67. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., Croce C.M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2257-2261.
68. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., Stephens R.M., Okamoto A., Yokota J., Tanaka T., Calin G.A., Liu C.G., Croce C.M., Harris C.C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
69. O'Connell R.M., Taganov K.D., Boldin M.P., Cheng G., Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1604-1609.
70. Tili E., Michaille J.J., Cimino A., Costinean S., Dumitru C.D., Adair B., Fabbri M., Alder H., Liu C.G., Calin G.A., Croce C.M. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 2007, 179:5082-5089.
71. Costinean S., Sandhu S.K., Pedersen I.M., Tili E., Trotta R., Perrotti D., Ciarlariello D., Neviani P., Harb J., Kauffman L.R., Shidham A., Croce C.M. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood 2009, 114:1374-1382.
72. O'Connell R.M., Chaudhuri A.A., Rao D.S., Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:7113-7118.
73. Sly L.M., Rauh M.J., Kalesnikoff J., Song C.H., Krystal G. LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity 2004, 21:227-239.
74. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. 2009, 9:550-562.
75. Palozza P., Torelli C., Boninsegna A., Simone R., Catalano A., Mele M.C., Picci N. Growth-inhibitory effects of the astaxanthin-rich alga Haematococcus pluvialis in human colon cancer cells. Cancer Lett. 2009, 283:108-117.
76. Colakoglu T., Yildirim S., Kayaselcuk F., Nursal T.Z., Ezer A., Noyan T., Karakayali H., Haberal M. Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence?. Am. J. Surg. 2008, 195:719-725.
77. Popivanova B.K., Kitamura K., Wu Y., Kondo T., Kagaya T., Kaneko S., Oshima M., Fujii C., Mukaida N. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 2008, 118:560-570.
78. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296.
79. Ceppi M., Pereira P.M., Dunand-Sauthier I., Barras E., Reith W., Santos M.A., Pierre P. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2735-2740.
80. Shibuya H., Iinuma H., Shimada R., Horiuchi A., Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 2010, 79:313-320.
81. Greither T., Grochola L.F., Udelnow A., Lautenschlager C., Wurl P., Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int. J. Cancer 2010, 126:73-80.
82. Budhu A., Ji J., Wang X.W. The clinical potential of microRNAs. J. Hematol. Oncol. 2010, 3:37.
83. Bluml S., Bonelli M., Niederreiter B., Puchner A., Mayr G., Hayer S., Koenders M.I., van den Berg W.B., Smolen J., Redlich K. Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum. 2011, 63:1281-1288.
84. Luo X., Burwinkel B., Tao S., Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer?. Cancer Epidemiol. Biomarkers Prev. 2011, 20:1272-1286.
85. Liu G., Friggeri A., Yang Y., Park Y.J., Tsuruta Y., Abraham E. miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:15819-15824.
86. Heinrich P.C., Behrmann I., Muller-Newen G., Schaper F., Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 1998, 334(Pt 2):297-314.
87. Terzic J., Grivennikov S., Karin E., Karin M. Inflammation and colon cancer. Gastroenterology 2010, 138:2101-2114. (e2105).
88. Krichevsky A.M., Gabriely G. miR-21: a small multi-faceted RNA. J. Cell. Mol. Med. 2009, 13:39-53.
89. Campoli M., Chang C.C., Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 2002, 20(Suppl. 4):A40-A45.
90. Nagel R., le Sage C., Diosdado B., van der Waal M., Oude Vrielink J.A., Bolijn A., Meijer G.A., Agami R. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008, 68:5795-5802.
91. Zhou W., Li X., Liu F., Xiao Z., He M., Shen S., Liu S. MiR-135a promotes growth and invasion of colorectal cancer via metastasis suppressor 1 in vitro. Acta Biochim. Biophys. Sin. 2012, 44:838-846.
92. Iacopetta B. Are there two sides to colorectal cancer?. Int. J. Cancer 2002, 101:403-408.
93. Li F.Y., Lai M.D. Colorectal cancer, one entity or three. J. Zhejiang Univ. (Sci.) 2009, 10:219-229.
94. H. Zhong, H.R. Wang, S. Yang, J.H. Zhong, T. Wang, C. Wang, F.Y. Chen, Targeting Smad4 links microRNA-146a to the TGF-beta pathway during retinoid acid induction in acute promyelocytic leukemia cell line, International Journal of Hematology, 92 129-135.
95. H. Shibuya, H. Iinuma, R. Shimada, A. Horiuchi, T. Watanabe, Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer, Oncology, 79 313-320.
96. Ekbom A., Helmick C., Zack M., Adami H.O. Ulcerative colitis and colorectal cancer. A population-based study, The New England journal of medicine 1990, 323:1228-1233.
97. Ekbom A., Helmick C., Zack M., Adami H.O. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990, 336:357-359.
98. Gillen C.D., Andrews H.A., Prior P., Allan R.N. Crohn's disease and colorectal cancer. Gut 1994, 35:651-655.
99. Gillen C.D., Walmsley R.S., Prior P., Andrews H.A., Allan R.N. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 1994, 35:1590-1592.
100. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115:182-205.
101. Sartor R.B. Clinical applications of advances in the genetics of IBD. Rev. Gastroenterol. Disord. 2003, 3(Suppl. 1):S9-S17.